Table 1. Characteristics of included studies for indirect meta-analysis.
| Lead author (y) | Trial name (phase) | Therapeutic regimen of TKI | Therapeutic regimen of Chemo | Exon of EGFR mutationa | Sample size (TKI/Chemo) | HRTKI/chemotherapy for PFS (95% CI) |
| Mok TS (2009) | IPASS (III) | Gefitinib 250 mg/d, po | Paclitaxel 200 mg/m2, d1, iv, q3w + carboplatin | 19 | 140 (66/74) | 0.38 (0.26–0.56) |
| (AUC = 5–6) d1, iv, q3w×6 cycles | 21 | 111 (64/47) | 0.55 (0.35–0.87) | |||
| Mitsudomi T (2010) | WJTOG3405 (III) | Gefitinib 250 mg/d, po | Docetaxel 60 mg/m2, d1, iv, q3w + cisplatin 80 | 19 | 87 (50/37) | 0.453 (0.268–0.768) |
| mg/m2, d1, iv, q3w×3–6 cycles | 21 | 85 (36/49) | 0.514 (0.294–0.899) | |||
| Zhou CC (2011) | OPTIMAL (III) | Erlotinib 150 mg/d, po | Gemcitabine 1000 mg/m2, d1,8, iv, q3w + | 19 | 82 (43/39) | 0.13 (0.07–0.25) |
| carboplatin (AUC = 5) d1, iv, q3w×4 cycles | 21 | 72 (39/33) | 0.26 (0.14–0.49) | |||
| Rosell R (2012) | EUTRAC (III) | Erlotinib 150 mg/d, po | Docetaxel 75 mg/m2, d1 or gemcitabine | 19 | 115 (57/58) | 0.30 (0.18–0.50) |
| 1000–1250 mg/m2, d1,8, iv, q3w + cisplatin 75 | ||||||
| mg/m2, d1 or carboplatin (AUC = 5–6) d1, iv, | 21 | 58 (29/29) | 0.55 (0.29–1.02) | |||
| q3w×4 cycles | ||||||
| Sequist LV (2013) | LUXLUNG3 (III) | Afatinib 40 mg/d, po | Pemetrexed 500 mg/m2, d1, iv, q3w + cisplatin | 19 | 170 (113/57) | 0.28 (0.18–0.44) |
| 75 mg/m2, d1, iv, q3w×≤6 cycles | 21 | 138 (91/47) | 0.73 (0.46–1.17) | |||
| Wu YL (2014) | LUXLUNG6 (III) | Afatinib 40 mg/d, po | Gemcitabine 1000 mg/m2, d1,8, iv, q3w + | 19 | 186 (124/62) | 0.20 (0.13–0.33) |
| cisplatin 75 mg/m2, d1, iv, q3w×≤6 cycles | 21 | 138 (92/46) | 0.32 (0.19–0.52) |
a
Exon of EGFR mutation means either exon 19 deletion or exon 21 L858R mutation.
Abbreviations: AUC = area under the concentration time curve; Chemo = chemotherapy; CI = confidence interval; EGFR = epidermal growth factor receptor; HR = Hazard ratio; PFS = progression-free survival; TKI = tyrosine kinase inhibitor.